secwatch / observer
8-K filed July 28, 2023, 7:59 PM ET CIK 0000810509
other material confidence high sentiment negative materiality 0.85

Navidea appoints Craig Dais as CFO; stockholders approve reverse split and preferred conversion

NAVIDEA BIOPHARMACEUTICALS, INC.

item 5.02item 5.07item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig Dais

Chief Financial Officer
NAVIDEA BIOPHARMACEUTICALS, INC.
Effective
2023-07-28
Filed
July 28, 2023, 7:59 PM ET
On July 26, 2023 the Board of Directors (the “Board”) of the Company appointed Craig Dais, age 57, as the Company’s Chief Financial Officer, effective upon his start date of July 28, 2023.
Departed

Joseph W. Meyer

Director, Finance and Accounting
NAVIDEA BIOPHARMACEUTICALS, INC.
Effective
2023-08-11
Successor
Craig Dais
Filed
July 28, 2023, 7:59 PM ET
On July 24, 2023, Joseph W. Meyer, Director, Finance and Accounting, Principal Financial Officer and Principal Accounting Officer of Navidea Biopharmaceuticals, Inc. (the “Company”), informed the Company of his resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig Dais was appointed as Chief Financial Officer at NAVIDEA BIOPHARMACEUTICALS, INC..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
On July 26, 2023 the Board of Directors (the “Board”) of the Company appointed Craig Dais, age 57, as the Company’s Chief Financial Officer, effective upon his start date of July 28, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph W. Meyer resigned as Director, Finance and Accounting at NAVIDEA BIOPHARMACEUTICALS, INC..

Action
resigned
Role
Director, Finance and Accounting
Exact text from the filing
On July 24, 2023, Joseph W. Meyer, Director, Finance and Accounting, Principal Financial Officer and Principal Accounting Officer of Navidea Biopharmaceuticals, Inc. (the “Company”), informed the Company of his resignation.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NAVIDEA BIOPHARMACEUTICALS, INC. shareholders approved Preferred Stock Conversion and Change of Control Proposal at the 2023-07-27 meeting.

Outcome
passed
Meeting
2023-07-27
Exact text from the filing
The Preferred Stock Conversion and Change of Control Proposal was approved by votes as follows: For Against Abstain 39,987,334 15,937,845 337,284 There were 8,441,135 broker non-votes on the Preferred Stock Conversion and Change of Control Proposal.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NAVIDEA BIOPHARMACEUTICALS, INC. shareholders approved Reverse Stock Split Proposal at the 2023-07-27 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-07-27
Exact text from the filing
The Reverse Stock Split Proposal was approved by votes as follows: For Against Abstain 47,907,056,197 16,512,206,711 349,038,690 There were no broker non-votes on the Reverse Stock Split Proposal.
View on SEC.gov

160 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Source: SEC EDGAR
accession 0001437749-23-021059
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.